Skip to content

Study · Randomized controlled trial · n = 179 · 2003

4 results

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ

The New England journal of medicine20 Sept 2003Cited by 788 (Europe PMC)

PMID14500804 (opens in a new tab)DOI10.1056/nejmoa031975 (opens in a new tab)PepBankPUB-14500804
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In osteoporotic postmenopausal women, the increase in trabecular spine volumetric density with PTH was about twice that with alendronate.

    In plain wordsIn osteoporotic women, PTH increased trabecular spine density about twice as much as alendronate.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseTrabecular spine volumetric density versus alendronate
    Study

    n = 179

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The volumetric density of the trabecular bone at the spine increased substantially in all groups, but the increase in the parathyroid hormone group was about twice that found in either of the other groups.
    2 context sentences
    Summary · context
    were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months.
    Summary · context
    Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography.
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women, spine BMD increased during PTH monotherapy, as it did in all treatment groups.

    In plain wordsIn osteoporotic women, spine bone density increased during PTH treatment and in all other treatment groups.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSpine BMD change
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The bone mineral density at the spine increased in all the treatment groups, and there was no significant difference in the increase between the parathyroid hormone group and the combination-therapy group.
    2 context sentences
    Summary · context
    were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months.
    Summary · context
    Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography.
  3. 03HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women, volumetric trabecular spine density increased substantially during PTH monotherapy, as it did in all groups.

    In plain wordsIn osteoporotic women, trabecular spine density increased during PTH treatment and in all other groups.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseTrabecular spine volumetric density change
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The volumetric density of the trabecular bone at the spine increased substantially in all groups, but the increase in the parathyroid hormone group was about twice that found in either of the other groups.
    2 context sentences
    Summary · context
    were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months.
    Summary · context
    Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography.
  4. 04HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women, bone formation increased markedly during PTH monotherapy.

    In plain wordsIn osteoporotic women, bone formation increased during PTH treatment.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBone formation change
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 microg daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone formation increased markedly in the parathyroid hormone group but not in the combination-therapy group.
    2 context sentences
    Summary · context
    were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months.
    Summary · context
    Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.